1180496-46-1Relevant articles and documents
Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320
Parsy, Christophe C.,Alexandre, Fran?ois-René,Bidau, Valérie,Bonnaterre, Florence,Brandt, Guillaume,Caillet, Catherine,Cappelle, Sylvie,Chaves, Dominique,Convard, Thierry,Derock, Michel,Gloux, Damien,Griffon, Yann,Lallos, Lisa B.,Leroy, Frederic,Liuzzi, Michel,Loi, Anna-Giulia,Moulat, Laure,Chiara, Musiu,Rahali, Houcine,Roques, Virginie,Rosinovsky, Elodie,Savin, Simon,Seifer, Maria,Standring, David,Surleraux, Dominique
, p. 5427 - 5436 (2015/11/09)
Exploration of the P2 region by mimicking the proline motif found in BILN2061 resulted in the discovery of two series of potent HCV NS3/4A protease inhibitors. X-ray crystal structure of the ligand in contact with the NS3/4A protein and modulation of the
MACROCYCLIC SERINE PROTEASE INHIBITORS
-
, (2010/11/03)
Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.